New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 21, 2013
08:06 EDTTEVA, ACTITeva's laquinimod for multiple sclerosis shows positive Phase 3 results
Teva and Active Biotech announced top-line results from the open-label extension of the Phase III ALLEGRO study that assessed the progression of disability and safety of oral laquinimod in early versus delayed-start relapsing-remitting multiple sclerosis patients. The study compared the effectiveness of laquinimod in patients who received 36 months (early-start) versus those who received 24 months of laquinimod treatment (delayed-start). Laquinimod is an oral, once daily, investigational drug in Phase III studies for RRMS. Overall, early start patients were less likely to experience disease progression than those with a delayed start of Laquinimod (11.8% risk of confirmed disability progression vs 16.7%). The study also supports a favorable safety and tolerability profile of laquinimod in RRMS patients. No new safety concerns arose during the open-label phase. Additionally, data suggests laquinimod has potential restorative and anti-inflammatory properties.
News For TEVA;ACTI From The Last 14 Days
Check below for free stories on TEVA;ACTI the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
September 29, 2014
07:19 EDTTEVAUBS to hold a field trip
Subscribe for More Information
05:26 EDTTEVAProtalix appoints Moshe Manor as CEO
Subscribe for More Information
September 17, 2014
11:01 EDTTEVAActavis drops after NY AG seeks to block Alzheimer drug switch
Subscribe for More Information
08:05 EDTTEVAEagle Pharm says Teva requests motion to dismiss Bendamustine lawsuit
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use